Cowen Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Outperform

March 1, 2021 5:48 AM EST
Get Alerts EYPT Hot Sheet
Price: $16.56 -0.9%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 2 | New: 5
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Cowen analyst Ken Cacciatore initiates coverage on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) with a Outperform rating and a price target of $25.00.

The analyst comments "EyePoint is leveraging their commercially-validated sustained release Durasert technology to develop a 6-month duration TKI (vorolanib) implant to treat wet AMD. We believe the company is uniquely positioned to develop EYP-1901, which, if successful, could represent a $500MM+ opportunity. The commercialized products augment the business."

For an analyst ratings summary and ratings history on EyePoint Pharmaceuticals, Inc. click here. For more ratings news on EyePoint Pharmaceuticals, Inc. click here.

Shares of EyePoint Pharmaceuticals, Inc. closed at $10.81 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Cowen & Co